AlphaFold predicted structure
FUT8 · Q9BYC5

Mean pLDDT
92.0/ 100
Very high
575 residues
Confidence breakdown
- Very high(≥ 90)77%
- Confident(70–90)15%
- Low(50–70)6%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
fucosyltransferase 8
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Congenital disorders of glycosylation
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
congenital disorder of glycosylation with defective fucosylation
Abnormality of the skeletal system
hereditary disease
gout
COVID-19
Seizure
Intellectual disability
myopathy
Genu varum
Genu valgum
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Alpha-(1,6)-fucosyltransferase
Catalyzes the addition of fucose in alpha 1-6 linkage to the first GlcNAc residue, next to the peptide chains in N-glycans (PubMed:17172260, PubMed:29304374, PubMed:36280670, PubMed:9133635). Fucosylates the reducing GlcNAc residue in complex-type N-glycans attached on the fragment crystallizable (Fc) of IgGs. Fully converts Fc glycoforms containing one or two terminal GlcNAc moieties (G0-GlcNAc and G0) (PubMed:36280670)
FUT8 · Q9BYC5

Mean pLDDT
92.0/ 100
Very high
575 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0